Summaries & Highlights

6 views 0 hours watched
10:01

2024 ASH Annual Meeting Insights Hub

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why and How

FEATURING Jean-Jacques Kiladjian
  • December 17, 2024
13:47

2024 ASH Annual Meeting Insights Hub

ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for Extended VTE Management

FEATURING Jordan Schaefer
  • 6 views
  • December 16, 2024

Lymphoma

8 views 0 hours watched
10:08

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Loncastuximab Tesirine and Rituximab in High-Risk R/R Follicular Lymphoma

FEATURING Juan Alderuccio
  • December 17, 2024
07:30

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Optimizing Tafa-Len in R/R DLBCL - GELTAMO Real-World Study

FEATURING Antonio Gutierrez
  • 6 views
  • December 16, 2024
13:39

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With MCL - MAVO Phase 1/2 Study

FEATURING Austin Kim
  • 2 views
  • December 13, 2024
05:49

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Real-World Outcomes With Evolving Management of CRS in CAR-T Therapy for NHL

FEATURING Radhika Bansal
  • December 13, 2024

Leukemia

10 views 0 hours watched
08:17

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ph3 CLL12 Trial - Impact of Ibrutinib on QoL in Pts With Early-Stage, Asymptomatic CLL

FEATURING Ellinor Goergen
  • December 17, 2024
05:58

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration

FEATURING Mazyar Shadman
  • December 17, 2024
10:17

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Venetoclax +/- Obinutuzumab vs. CIT for 1L CLL

FEATURING Jennifer Brown
  • December 17, 2024
08:51

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: GLOW Study 64-Month Follow-Up - 1L Ibrutinib + Venetoclax vs. Chlorambucil + Obinutuzumab in Elderly/Frail CLL

FEATURING Carsten Utoft Niemann
  • 1 view
  • December 16, 2024
05:36

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results

FEATURING Amir Fathi
  • December 16, 2024
06:47

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Epcoritamab Monotherapy in R/R CLL - Expansion and Optimization Cohort Results From EPCORE CLL-1

FEATURING Alexey Danilov
  • 1 view
  • December 16, 2024
21:24

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy

FEATURING Justin Watts
  • 1 view
  • December 16, 2024
11:22

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease

FEATURING Matthew Davids
  • 4 views
  • December 13, 2024
05:07

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML

FEATURING Maria Amaya
  • 2 views
  • December 13, 2024

Myeloma

4 views 0 hours watched
10:03

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: VRD Consolidation and Len Maintenance in MM - Long-Term EMN02/HOVON95 Ph3 Study Results

FEATURING Pieter Sonneveld
  • 1 view
  • December 17, 2024
06:10

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L ASCT - KarMMa-2 Trial Follow-Up

FEATURING Barry Paul
  • December 17, 2024
04:01

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Optimizing Therapy Duration for Transplant-Ineligible NDMM - Long-Term UK Myeloma XI Data

FEATURING Charlotte Pawlyn
  • December 16, 2024
05:58

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone in RRMM

FEATURING Muhamed Baljevic
  • 1 view
  • December 16, 2024
10:37

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From CAR-PRISM Study

FEATURING Omar Nadeem
  • 1 view
  • December 16, 2024
13:32

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Analyses of MRD Negativity Dynamics in the Phase 3 IMROZ Study - Isa-VRd in Patients With Newly Diagnosed MM

FEATURING Robert Z. Orlowski
  • 1 view
  • December 13, 2024
07:15

2024 ASH Annual Meeting Insights Hub

Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for R/R MM in Community Settings - Focusing on Bispecific Antibody Therapy

FEATURING Benjamin Derman
  • December 13, 2024

MDS & MPN

2 views 0 hours watched
10:01

2024 ASH Annual Meeting Insights Hub

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why and How

FEATURING Jean-Jacques Kiladjian
  • December 17, 2024
06:20

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Effect of Prior Treatments on Imetelstat in Transfusion-Dependent Pts With ESA-Relapsed or Refractory/Ineligible LR-MDS

FEATURING Uwe Platzbecker
  • 1 view
  • December 16, 2024
11:30

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Clinical Importance of Achieving Hb ≥10 g/dL in Transfusion-Dependent ESA-Naïve LR-MDS Pts Treated With Luspatercept - COMMANDS Trial

FEATURING Valeria Santini
  • December 16, 2024

Benign Hematology

6 views 0 hours watched
13:47

2024 ASH Annual Meeting Insights Hub

ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for Extended VTE Management

FEATURING Jordan Schaefer
  • 6 views
  • December 16, 2024